局限性和转移性前列腺癌中神经肽Y表达的转录组学与临床特征:一种具有临床意义的新型前列腺癌亚型的识别
该研究利用全基因组表达谱分析三个局限性前列腺癌队列(总n=18818)和五个转移性去势抵抗性前列腺癌队列(总n=495),刻画神经肽Y(NPY)表达特征。低NPY表达与侵袭性分级分组5疾病、更高基因组风险及更短的无转移生存和无进展生存相关。低NPY/ERG+亚型转移风险最高(HR 2.2),高NPY/ERG-亚型转移风险最低(HR 0.53)。
要点
- 低NPY表达与侵袭性分级分组5疾病、更高基因组风险和更短的无转移生存相关。
- 低NPY/ERG+亚型的基因组转移风险最高,转移率最高(HR 2.2)。
- 高NPY/ERG-亚型的基因组转移风险最低,转移率最低(HR 0.53)。
核心结论
- 低NPY表达与不良基因组特征及临床相关性和结局相关。
- 低NPY/ERG+亚型与最高转移风险相关。
- 基于NPY表达和ERG融合状态进行预后亚分组和个体化治疗值得进一步研究。
研究设计与样本
- 对三个局限性前列腺癌队列(总n=18818)和五个转移性去势抵抗性前列腺癌队列(总n=495)进行全基因组表达谱分析。
- 所有局限性前列腺癌患者均接受根治性前列腺切除术。
- 根据NPY表达将患者分为低NPY和高NPY组,并结合ERG融合状态定义四个亚组。
- 采用Cox比例风险模型对根治性前列腺切除术后远处转移时间进行建模。
- 基于22基因特征对前瞻性样本计算转移基因组风险评分。
主要发现
- 在TCGA泛癌队列(n=9483)中,NPY在前列腺癌中表达最高(p<0.0001)。
- 在17967例前瞻性样本中,低NPY表达与侵袭性分级分组5疾病和更高基因组风险相关(p<0.0001)。
- 在回顾性队列(n=355)中,低NPY与更短的无转移生存相关(p=0.001);在TCGA队列(n=497)中,低NPY与更短的无进展生存相关(p=0.001)。
- 在mCRPC队列中,低NPY与神经内分泌发展相关(p<0.01)。
- 低NPY/ERG+亚型与最高基因组转移风险相关(p<0.0001),且与所有其他亚型相比转移率最高(HR 2.2 [1.22-4.03],p=0.008)。
关键数值与推荐
- 在TCGA泛癌队列(n=9483)中,NPY在前列腺癌中表达最高,p<0.0001。
- 在17967例前瞻性样本中,低NPY表达与分级分组5疾病及更高基因组风险相关,p<0.0001。
- 回顾性队列(n=355)中低NPY与更短无转移生存相关,p=0.001;TCGA队列(n=497)中低NPY与更短无进展生存相关,p=0.001。
- mCRPC队列中低NPY与神经内分泌发展相关,p<0.01。
- 低NPY/ERG+亚型转移风险HR 2.2(95%CI 1.22-4.03),p=0.008;高NPY/ERG-亚型转移风险HR 0.53(95%CI 0.35-0.81),p=0.003。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文结论指出,基于NPY表达和ERG融合状态的预后亚分组和个体化治疗值得进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tumor microenvironment and its interaction with neuroendocrine modulators contribute to prostate carcinogenesis and progression. OBJECTIVE: We sought to define the transcriptomic and clinical implications of neuropeptide Y (NPY) expression in prostate cancer progression. DESIGN, SETTING, AND PARTICIPANTS: Genome-wide expression profiling of three localized prostate cancer (total n=18818) and five metastatic castrate-resistant prostate cancer (mCRPC; total n=495) cohorts was used to characterize NPY expression. All men underwent radical prostatectomy (RP) for localized prostate cancer. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Patients were grouped into those with low NPY and high NPY based on NPY expression. Associations between these groups and histological, genomic, and clinical outcomes including progression-free survival (PFS) and metastases-free survival (MFS) were examined. Combining ERG-fusion status with NPY expression, four groups were defined (lowNPY/ERG+, lowNPY/ERG-, highNPY/ERG+, and highNPY/ERG-). Cox proportional hazards modeled the time to distant metastasis after RP. Genomic risk scores for metastasis were calculated for prospective samples, based on a 22-gene signature. RESULTS AND LIMITATIONS: Across cancers, NPY showed the highest expression in prostate cancer in The Cancer Genome Atlas (TCGA) PAN-Cancer cohort (n=9483, p<0.0001). In 17967 prospective samples, low NPY expression was associated with aggressive grade group 5 disease and a higher genomic risk (p<0.0001). In the retrospective (n=355) and TCGA (n=497) cohorts, low NPY was associated with shorter MFS and PFS, respectively (p=0.001 for both). In mCRPC cohorts, low NPY was associated with neuroendocrine development (p<0.01). NPY was highly correlated to ERG; thus, we defined four groups based on NPY expression and ERG fusion. The lowNPY/ERG+ subtype was associated with the highest genomic risk for metastasis (p<0.0001) and the highest rate of metastasis compared with all other subtypes (hazard ratio [HR]: 2.2 [1.22-4.03], p=0.008), while the highNPY/ERG- subtype was associated with the lowest genomic risk for metastasis (p<0.0001) and the lowest rate of metastasis (HR: 0.53 [0.35-0.81], p=0.003). CONCLUSIONS: Low NPY expression is associated with adverse genomic features and clinical correlates and outcomes. The lowNPY/ERG+ subtype was associated with the highest risk of developing metastasis. Prognostic subgrouping and tailored treatments by NPY expression and ERG fusion status warrant further study. PATIENT SUMMARY: The low neuropeptide Y prostate cancer subtype appears to be aggressive with a high risk of developing metastasis.
引用
- Alshalalfa M, Nguyen PL, Beltran H, et al. Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications. Eur Urol Oncol. 2019. PMID: 31164324. doi:10.1016/j.euo.2019.05.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。